Weight loss drug side effects compared: nausea, GI issues, and quit rates
Last reviewed: April 2026·Based on 3 clinical trials·Every claim linked to source
Quick read · 6 min
Nausea is the #1 reason people worry about starting weight loss medication — and the #1 reason some people stop. Here is exactly how the three newest drugs compare, using data from their largest clinical trials.
In simple terms:
•While the side effect percentages might seem high, over 90% of people stayed on therapy in all three major trials
•Tirzepatide (Zepbound) has the lowest side effect rates across the board — 31% nausea vs 44% for semaglutide
•Orforglipron (Foundayo) falls in the middle — 33% nausea, but lowest diarrhoea rate at 15%
•Side effects peak during dose increases and typically settle by weeks 12–16
93%
stayed on Wegovy
(7% quit from side effects)
94%
stayed on Zepbound
(6% quit from side effects)
92%
stayed on Foundayo
(8% quit from side effects)
Side-by-side: how the three drugs compare
Each percentage below represents the share of trial participants who experienced that side effect at any point during the study. Higher bars mean more people were affected.
Nausea
Wegovy
44%
Zepbound
31%
Foundayo
33%
Vomiting
Wegovy
24%
Zepbound
18%
Foundayo
19%
Diarrhoea
Wegovy
30%
Zepbound
23%
Foundayo
15%
Constipation
Wegovy
24%
Zepbound
17%
Foundayo
18%
Fatigue
Wegovy
11%
Zepbound
7%
Foundayo
6%
Indigestion
Wegovy
9%
Zepbound
10%
Foundayo
10%
✓ Zepbound: Lowest nausea (31%)
✓ Foundayo: Lowest diarrhoea (15%)
✓ Zepbound: Lowest quit rate (6%)
Key insight
Tirzepatide (Zepbound) consistently has the lowest rates for the most bothersome side effects — nausea, vomiting, and diarrhoea. But the differences between tirzepatide and orforglipron are small (1–2 percentage points for nausea and vomiting). The bigger gap is between these two and semaglutide, which has notably higher nausea (44%) and diarrhoea (30%).
When do side effects peak? A typical timeline
Side effects are not constant. They follow a predictable pattern tied to dose increases:
Weeks 1–2
Starting dose — mildest
Most people start at the lowest dose. Nausea affects roughly 1 in 3 people, usually mild. The body is adjusting.
Weeks 3–8
Dose increases — worst window
Each dose increase can trigger a new wave of nausea. This is the period when most people feel the worst. It usually passes within 3–5 days per increase.
Weeks 8–16
Settling down
For most people, GI side effects become significantly milder or disappear entirely as the body adapts to the maintenance dose.
Week 16+
Maintenance — steady state
The majority of people who stayed through the adjustment period report minimal or no ongoing GI issues.
How to reduce side effects
🍽️
Eat smaller, more frequent meals
Large meals overwhelm a slower-emptying stomach. 4–5 small meals instead of 2–3 large ones makes a significant difference.
🚫
Avoid fatty and fried foods
High-fat meals sit in the stomach longer and are the most common nausea trigger. Lean protein and vegetables are easier to tolerate.
🐢
Eat slowly
Eating too fast before your brain registers fullness is the top cause of post-meal nausea. Take 20+ minutes per meal.
💧
Stay hydrated
Sip water throughout the day. Dehydration worsens nausea and is common when appetite is reduced and you are eating less food.
⏰
Consistent timing
Take your medication at the same time each week (injections) or day (pills). Consistency helps the body adapt.
📈
Slow titration
Stay at each dose for the full 4 weeks before increasing. If side effects are severe, your doctor can extend the titration period.
Full side effect profiles
Semaglutide (Wegovy)
Weekly injection
STEP 1 · 1,961 participants
Nausea44%
Vomiting24%
Diarrhoea30%
Constipation24%
Abdominal pain20%
Fatigue11%
Indigestion9%
Stayed on medication93%
Quit due to side effects7%
Tirzepatide (Zepbound)
Weekly injection
SURMOUNT-1 · 2,539 participants
Nausea31%
Vomiting18%
Diarrhoea23%
Constipation17%
Abdominal pain9%
Fatigue7%
Indigestion10%
Stayed on medication94%
Quit due to side effects6%
Orforglipron (Foundayo)
Daily pill
ATTAIN-1 · 989 participants
Nausea33%
Vomiting19%
Diarrhoea15%
Constipation18%
Fatigue6%
Indigestion10%
Stayed on medication92%
Quit due to side effects8%
Bottom line
→Best overall GI profile: Tirzepatide (Zepbound) — lowest nausea, vomiting, diarrhoea, and quit rate
→Middle ground: Orforglipron (Foundayo) — similar to tirzepatide, with the lowest diarrhoea rate. Daily pill, no injection.
→Higher side effects but proven track record: Semaglutide (Wegovy) — more nausea, but longest real-world data and proven heart benefit
→Key context: Over 90% of people stuck with all three drugs. Side effects peak during dose increases and typically resolve by weeks 12–16.
Based on clinical trials · No rankings · Every claim linked to source
Last reviewed: April 2026
Medical disclaimer: This website is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare provider before starting, stopping, or changing any treatment.